Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with a rising global incidence. 1 The majority of HCC occurs in the setting of liver cirrhosis, mainly due to hepatitis C virus (HCV) infection, hepatitis B viral infection, alcohol consumption, or nonalcoholic fatty liver disease.
several clinical trials, more than 90 % of patients achieved sustained viral response (SVR) with sofosbuvir, 4 ,5 simeprevir, 6 or ledipasvir. 7 High efficacy was shown among all subgroups, except for genotypes 1 and 4. While still unclear, the curative effect of these new therapies will probably affect the incidence of HCC.
Management of HCC remains a multidisciplinary approach, especially in the presence of curative treatments in early stage. Screening, risk stratification, and management of liver decompensation are crucial in patient care.
Surgery, liver transplant, and radiofrequency ablation remain the standard of care for the curative treatment of early-stage HCC. 8 Transarterial chemoembolization (TACE) is the most widely used modality for nonresectable tumors. 9 Recently, transarterial embolization (TAE) has shown similar outcome and safety profiles, 10 questioning the role of adding doxorubicin. Radioembolization with Y90 is challenging the current paradigm of HCC treatment, despite the lack of any randomized clinical trial data to date. 11 Enhancing the treatment effect of antiangiogenic therapy by preventing the angiogenic flare of sorafenib has failed so far.
12,13
The advent of sorafenib as a standard of care with an improvement in survival to 10.7 months compared with 7.9 months for placebo (0.69; 95 % confidence interval [CI] 0.55-0.87; p=0.001) opened the door into ample opportunities for the evaluation of other therapeutic options.
14 A randomized phase II study of sorafenib plus doxorubicin in firstline treatment of HCC showed improvement in overall survival (OS) of 13.7 months compared with 6.5 months for doxorubicin plus placebo (p=0.0049). 15 A large randomized phase III trial followed that. 16 However, the study was halted in view of an interim analysis that showed that "it is very unlikely that significant differences in overall survival and progression-free survival will be shown between the treatment arms", 5 based on CALGB 80802 communication.
Abstract
Recent advances in the understanding and management of hepatocellular carcinoma are promising and may usher in a new era in cancer therapy. Here we discuss the latest improvement in hepatitis C antiviral therapy, loco-regional tumor control, c-met inhibitors, and immune therapy. Genetic testing in hepatocellular carcinoma could be a turning point in the treatment development of this fatal disease. 
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